EUCTR2008-007097-38-BE
进行中（未招募）
1 期
A randomized, open-label Phase II study of BIBW 2992 versus cetuximab (Erbitux®) in patients with metastatic or recurrent Head and Neck Squamous Cell Carcinoma (HNSCC) after failure of platinum-containing therapy with a cross-over period for progressing patients.
SCS Boehringer Ingelheim Comm.V0 个研究点目标入组 146 人2009年1月12日
相关药物Erbitux®
概览
- 阶段
- 1 期
- 干预措施
- 未指定
- 疾病 / 适应症
- 未指定
- 发起方
- SCS Boehringer Ingelheim Comm.V
- 入组人数
- 146
- 状态
- 进行中（未招募）
- 最后更新
- 4年前
概览
简要总结
暂无简介。
研究者
入排标准
入选标准
- •Metastatic (stage IV) or recurrent HNSCC
- •Histologically or cytologically confirmed diagnosis of squamous cell carcinomas of the head and the neck.
- •Patients must have documented progressive disease following receipt of prior platinum\-based therapy.
- •Patients must have measurable disease as defined by RECIST criteria.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1\.2 Adults (18\-64 years) yes
- •F.1\.2\.1 Number of subjects for this age range
- •F.1\.3 Elderly (\>\=65 years) yes
- •F.1\.3\.1 Number of subjects for this age range
排除标准
- •Progressive disease within 3 months after completion of curative intent treatment for localized/locoregionally advanced disease.
- •Prior use of an EGFR or erbB2 inhibitor in the recurrent/metastatic disease setting
- •More than 2 chemotherapeutic regimens given for recurrent/metastatic disease.
- •Gastrointestinal disorders that may interfere with the absorption of the study drug or chronic diarrhea.
- •Use of alcohol or drugs incompatible with patient participation in the study in the investigator's opinion.
结局指标
主要结局
未指定
相似试验
进行中（未招募）
1 期
A randomized, open-label Phase II study of BIBW 2992 versus cetuximab (Erbitux®) in patients with metastatic or recurrent Head and Neck Squamous Cell Carcinoma (HNSCC) after failure of platinum-containing therapy with a cross-over period for progressing patients.Metastatic or recurrent Head and Neck Squamous Cell CarcinomaEUCTR2008-007097-38-FRBoehringer-Ingelheim France146
已完成
不适用
A Randomised, Open-label, Phase III Study of BIBW 2992 Versus Chemotherapy as First-line Treatment for Patients With Stage IIIB or IV Adenocarcinoma of the Lung Harbouring an EGFR Activating Mutatio-C34 Malignant neoplasm of bronchus and lungMalignant neoplasm of bronchus and lungC34PER-115-09Boehringer Ingelheim Pharmaceuticals, Inc. (BIPI),7
进行中（未招募）
1 期
A Phase II single-arm trial of BIBW 2992 in demographically and genotypically selected non-small cell lung cancer patients - BIBW 2992 in demographically / genotypically NSCLCpatients with non-small cell lung cancer in stage IIB / IVEUCTR2008-001546-67-BESCS Boehringer Ingelheim Comm.V40
招募中
2 期
Afatinib in HER2 (Human Epidermal Growth Factor Receptor)-Treatment FailuresCTRI/2011/07/001915Boehringer Ingelheim Pharmaceuticals120
已完成
不适用
6 Weeks Treatment of Locally Advanced Breast Cancer With BIBW 2992 (Afatinib) or Lapatinib or Trastuzumab-C50 Malignant neoplasm of breastMalignant neoplasm of breastC50PER-056-09Boehringer Ingelheim Pharmaceuticals, Inc. (BIPI),